Please login to the form below

Not currently logged in
Email:
Password:

migraine drug

This page shows the latest migraine drug news and features for those working in and with pharma, biotech and healthcare.

AbbVie shares positive phase 3 results for migraine drug Qulipta

AbbVie shares positive phase 3 results for migraine drug Qulipta

for more than three months, which on at least eight days per month has features of migraine headache. ... The trial involved 778 patients with at least a one-year history of chronic migraine and were randomised into one of three treatment groups.

Latest news

  • Pfizer snaps up Biohaven’s migraine drug for $1.24bn Pfizer snaps up Biohaven’s migraine drug for $1.24bn

    Pfizer will sell the migraine drug outside the US and will also gain the rights to a second drug. ... Neuroscience specialist Biohaven Pharmaceuticals has teamed up with Pfizer to commercialise its recently launched migraine drug Nurtec ODT (rimegepant)

  • Biohaven gets FDA approval for migraine drug Nurtec ODT Biohaven gets FDA approval for migraine drug Nurtec ODT

    Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... US, which said last week the drug would be cost-effective at $4,

  • Lundbeck gets US approval for migraine drug at heart of Alder takeover Lundbeck gets US approval for migraine drug at heart of Alder takeover

    specialists aren’t rushing to switch wholesale from other migraine preventative therapies like Allergan’s Botox. ... Aimovig’s ex-US licensee Novartis didn’t break sales of the drug in its fourth quarter statement.

  • Allergan gets FDA nod for first oral CGRP drug for migraine Allergan gets FDA nod for first oral CGRP drug for migraine

    The US regulator has given a green light to  Ubrelvy (ubrogepant) for acute migraine with or without aura, and Ireland-domiciled Allergan says it intends to launch the drug in the ... Ubrelvy represents an important new option for the acute treatment of

  • Amgen exits neuroscience R&D to focus on growth areas Amgen exits neuroscience R&D to focus on growth areas

    The unit scored a victory with the recent approval and launch of chronic migraine drug  Aimovig (erenumab), but earlier this year was forced to abandon its  umibecestat candidate for Alzheimer’s ... disease after trials suggested patients did worse

More from news
Approximately 1 fully matching, plus 48 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....